In this review, we will focus on B cell abnormalities and the rationale behind B-cell depletion therapy with anti-CD20 monoclonal antibody (mAb), rituximab, will be explored including an …

抗CD19单克隆抗体可能是比针对SLE的抗CD20单克隆抗体更有效的耗竭疗法，因为CD19在浆母细胞，长寿浆细胞和不表达CD20的早期B细胞上表达。

Anti-CD20 mAbs in systemic lupus erythematosus SLE is a chronic inflammatory disease with prominent immunologic abnormalities including antinuclear antibodies that can impact virtually …

Thirty of 36 (83%) patients with lupus nephritis (WHO II: 2, III: 5, IV: 22, V: 4, IV+V: 2, not assessed: 1) and 22 of 24 patients (92%) with neuropsychiatric SLE, who could be followed at …

The amount of anti-dsDNA and immunoglobin G (IgG) secreted by CD19 + CD20 +/- B cells was measured by enzyme-linked immunosorbent assay. Results: CD19 + CD20 - B cell frequency …

2024年2月6日 · CD20单抗 (如利妥昔单抗 [RTX])通常用于治疗严重或难治性系统性红斑狼疮 (SLE)。 新一代人源化CD20单抗，如奥法妥木单抗和奥瑞利珠单抗已被建议作为 ...

2023年9月5日 · 测试mosunetuzumab在SLE治疗中的基本原理正是基于该假设。 与其他抗CD20分子相比，Mosunetuzumab基于T细胞依赖性机制，更广泛地杀伤组织浸润B细胞，并且更有效 …

2024年4月1日 · Anti-C20 monoclonal antibodies (MAb), such as rituximab, are commonly used for the treatment of patients with severe or refractory systemic lupus erythematosus (SLE) but …

Rituximab (RTX), an anti-CD20 mAb, has been explored in SLE, given its B cell specificity and its efficacy in many other rheumatologic diseases. Belimumab (BEL), a mAb with specificity for B …

Ocrelizumab is a fully humanized monoclonal antibody against CD20, with higher ADCC activity and lower CDC effects compared to rituximab in SLE patients. 73 The phase III randomized, …